Re-Vana Therapeutics is an ocular pharmaceutical​ and drug delivery company focused on the development and commercialisation of revolutionary long-acting biodegradable drug delivery platforms to treat chronic eye diseases such as age-related macular degeneration, diabetic retinopathy, glaucoma and ocular infections.


Pharmaceutical

Re-Vana Therapeutics

Michael O’rourke

Gregoire Schwach

Wenrui Zhang

Sandip Gite

Shivanki Sahay

Peter McKenna

Jenna Hewitt

Lucy Finlay

Ravi Deevi

Sangdi Wang

Patrick H O’ruane

Tom Biancardi

Thakur Raghu Raj Singh

David Waite

The board of directors at Re-Vana Therapeutics has a wealth of experience in the pharmaceutical industry and in academia. The CEO, QUBIS Ltd, is also the Director of Innovation at Queen's University Belfast, and the Director at Networthnet Ltd. The company's creator and moderator, The Innovation Commons, is also the Past-President European Federation for Pharmaceutical Sciences at EUFEPS. Other consultants include Ferring Pharmaceuticals and www.kalarx.com. at Kala Pharmaceuticals.

Board of Directors

Leadership Team

CEO and Executive Team

Board of Directors

About

Team members

Other teams at Re-Vana Therapeutics

Leadership Team

CEO and Executive Team